S-Space College of Medicine/School of Medicine (의과대학/대학원) Urology (비뇨기과학전공) Journal Papers (저널논문_비뇨기과학전공)
Favorable intermediate risk prostate cancer with biopsy Gleason score of 6
|dc.contributor.author||Oh, Jong Jin||-|
|dc.contributor.author||Hwang, Sung Il||-|
|dc.contributor.author||Lee, Hak Jong||-|
|dc.contributor.author||Hong, Sung Kyu||-|
|dc.identifier.citation||BMC Urology. 2021 Apr 05;21(1):52||ko_KR|
To identify potential prognostic factors among patients with favorable intermediate risk prostate cancer with a biopsy Gleason score 6.
From 2003 to 2019, favorable intermediate risk patients who underwent radical prostatectomy were included in this study. All patients were evaluated preoperatively with MRI. Using PI-RADS scores, patients were divided into two groups, and clinic-pathological outcomes were compared. The impact of preoperative factors on significant pathologic Gleason score upgrading (≥ 4 + 3) and biochemical recurrence were assessed via multivariate analysis. Subgroup analysis was performed in patients with PI-RADS ≤ 2.
Among the 239 patients, 116 (48.5%) were MRI-negative (PI-RADS ≤ 3) and 123 (51.5%) were MRI-positive (PI-RADS > 3). Six patients in the MRI-negative group (5.2%) were characterized as requiring significant pathologic Gleason score upgrading compared with 34 patients (27.6%) in the MRI-positive group (p < 0.001). PI-RADS score was shown to be a significant predictor of significant pathologic Gleason score upgrading (OR = 6.246, p < 0.001) and biochemical recurrence (HR = 2.595, p = 0.043). 10-years biochemical recurrence-free survival was estimated to be 84.4% and 72.6% in the MRI-negative and MRI-positive groups (p = 0.035). In the 79 patients with PI-RADS ≤ 2, tumor length in biopsy cores was identified as a significant predictor of pathologic Gleason score (OR = 11.336, p = 0.014).
Among the patients with favorable intermediate risk prostate cancer with a biopsy Gleason score 6, preoperative MRI was capable of predicting significant pathologic Gleason score upgrading and biochemical recurrence. Especially, the patients with PI-RADS ≤ 2 and low biopsy tumor length could be a potential candidate to active surveillance.
|dc.subject||Intermediate risk group||-|
|dc.title||Favorable intermediate risk prostate cancer with biopsy Gleason score of 6||ko_KR|
- Appears in Collections:
- College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)